Verisk Analytics (NasdaqGS:VRSK) Q4 2025 Earnings call February 18, 2026 08:30 AM ET Company ParticipantsElizabeth Mann - CFOFaiza Alwy - Managing Director of U.S. Company ResearchGregory Peters - Managing DirectorLee Shavel - President and CEOScott Wurtzel - Director Equity ResearchStacey Brodbar - Head of Investor RelationsNone - Company RepresentativeConference Call ParticipantsAndrew Nicholas - VP and Senior Equity Research AnalystDavid Paige - Equity Research AnalystGeorge Tong - Managing Director and ...

The Vita Coco Company (NasdaqGS:COCO) Q4 2025 Earnings call February 18, 2026 08:30 AM ET Company ParticipantsCorey Baker - CFOJohn Mills - Managing PartnerMartin Roper - CEOMike Kirban - Executive ChairmanConference Call ParticipantsEric Des Lauriers - Senior Research AnalystJim Salera - Research AnalystLuke Maloney - Equity Research AnalystOperatorHello, and welcome to the Vita Coco Company's Fourth Quarter and Full Year 2025 Earnings Conference Call. My name is Liz. I'll be coordinating your call today. ...

Quad/Graphics (NYSE:QUAD) Q4 2025 Earnings call February 18, 2026 08:30 AM ET Company ParticipantsJoel Quadracci - Chairman and CEOJulie Currie - EVP and Chief Revenue OfficerTony Staniak - CFO and TreasurerConference Call ParticipantsBarton Crockett - Managing Director and Senior Research AnalystKevin Steinke - Equity Research AnalystOperatorA slide presentation accompanies today's webcast, and participants are invited to follow along, advancing the slides themselves. To access the webcast, follow the inst ...

PROG (NYSE:PRG) Q4 2025 Earnings call February 18, 2026 08:30 AM ET Company ParticipantsAlessandra Jimenez - Senior Equity Research AssociateBrad Thomas - Associate Director of ResearchBrian Garner - CFOHarold Goetsch - Senior Managing Director and Head of Fintech and FinancialsHoang Nguyen - Equity ResearchJohn Baugh - VP of Investor RelationsKyle Joseph - Managing DirectorSteve Michaels - President and CEOConference Call ParticipantsAnthony Chukumba - Managing Director and Senior Research AnalystEunice Ah ...

The Andersons (NasdaqGS:ANDE) Q4 2025 Earnings call February 18, 2026 08:30 AM ET Company ParticipantsBill Krueger - President and CEOBrian Valentine - EVP and CFOMike Hoelter - VP of Corporate Controller and Investor RelationsConference Call ParticipantsBen Klieve - Equity Research AnalystBen Mayhew - AnalystPooran Sharma - AnalystOperatorAs a reminder, this conference is being recorded for playback purposes. I will now hand the presentation to your host for today, Mr. Mike Hoelter, Vice President, Corpora ...

Perion Network (NasdaqGS:PERI) Q4 2025 Earnings call February 18, 2026 08:30 AM ET Company ParticipantsElad Tzubery - CFOTal Jacobson - CEO and DirectorNone - Video NarratorConference Call ParticipantsAndrew Marok - AnalystEric Martinuzzi - Senior Research AnalystJason Kreyer - Senior Research AnalystJeff Martin - Co-Director of Research and Senior Research AnalystLaura Martin - Senior Entertainment and Internet AnalystSteve Orman - AnalystOperatorHello everybody, and Welcome to the Perion Network Q4 and Fu ...

Ferroglobe (NasdaqCM:GSM) Q4 2025 Earnings call February 18, 2026 08:30 AM ET Company ParticipantsAlex Rotonen - VP of Investor RelationsBeatriz García-Cos - CFOMarco Levi - CEOConference Call ParticipantsMartin Englert - Senior Equity Research AnalystNick Giles - Senior Research AnalystOperatorAs a reminder, this conference call may be recorded. I would now like to turn the call over to Alex Rotonen, Ferroglobe's Vice President of Investor Relations. You may begin.Alex RotonenGood morning, everyone, and th ...

Cinemark (NYSE:CNK) Q4 2025 Earnings call February 18, 2026 08:30 AM ET Company ParticipantsChanda Brashears - SVP of Investor RelationsDrew Crum - Managing DirectorEric Wold - Executive Director of Equity ResearchMelissa Thomas - CFOOmar Mejias - VP of Equity ResearchSean Gamble - President and CEOStephen Laszczyk - VPConference Call ParticipantsChad Beynon - Managing Director and Senior AnalystDavid Karnovsky - Senior Research AnalystEric Handler - Managing Director and Senior Research AnalystMike Hickey ...

Summary of Sensei Biotherapeutics and Faeth Therapeutics Acquisition Conference Call Company and Industry Overview - **Company**: Sensei Biotherapeutics (NasdaqGM:SNSE) - **Acquisition Target**: Faeth Therapeutics - **Industry**: Biotechnology, specifically focused on cancer treatment Key Points and Arguments 1. **Acquisition Announcement**: Sensei Biotherapeutics announced the acquisition of Faeth Therapeutics, which includes a concurrent financing and changes to the leadership team and board of directors [2][6] 2. **Strategic Rationale**: The acquisition is seen as a means to maximize shareholder value and is expected to create significant value for stockholders [6] 3. **Faeth's Pipeline**: Faeth is a clinical-stage company developing multi-node therapies aimed at blocking cancer growth signals, with its lead asset, PIKTOR, showing promising safety and efficacy data [6][7] 4. **Financing Details**: Sensei entered into a $200 million private placement with support from leading healthcare investors, which will strengthen its financial position [8] 5. **Cash Runway**: The combined cash from the private placement and existing funds is expected to extend Sensei's cash runway through multiple clinical milestones [8] 6. **Leadership Changes**: Anand Parikh, former CEO and co-founder of Faeth, has joined Sensei as COO and a board member [9] 7. **PIKTOR Overview**: PIKTOR is an investigational oral combination therapy targeting the PI3K/AKT/mTOR pathway, designed to improve tolerability and efficacy compared to traditional treatments [10] 8. **Clinical Trial Results**: In a phase 1b trial, PIKTOR achieved a 47% overall response rate in heavily pre-treated patients with various cancers, including an 80% response rate in endometrial cancer patients [11] 9. **Future Trials**: PIKTOR is currently in phase 2 trials for endometrial cancer, with plans for additional studies in breast cancer and other tumor types [12] 10. **Market Potential**: The focus on cancers with mutations in the PI3K/AKT/mTOR pathway presents a significant market opportunity, particularly as treatment standards evolve towards combination strategies [13] 11. **Preclinical Pipeline**: In addition to PIKTOR, Sensei has a preclinical pipeline that includes therapies for rectal cancer and pediatric rare diseases [13] 12. **Acquisition Structure**: The acquisition was structured as a stock-for-stock merger, with Faeth's equity exchanged for Sensei common stock and newly created Series B non-voting convertible preferred stock [15] 13. **Ownership Post-Acquisition**: Post-acquisition, Faeth's equity holders will own approximately 40.8% of Sensei's common stock, while private placement investors will own about 54.3% [17] 14. **Use of Proceeds**: Proceeds from the private placement will primarily be used to advance PIKTOR for key clinical readouts [17] Additional Important Information - **Forward-Looking Statements**: The call included forward-looking statements regarding the expected effects and opportunities related to the acquisition, which involve risks and uncertainties [3][4] - **Investor Communication**: Investors are encouraged to read the proxy statement and other relevant materials filed with the SEC for important information regarding the transactions [5] - **Future Updates**: Sensei plans to provide updates on the progress of its clinical trials and the integration of Faeth in the coming weeks and months [19]

HF Sinclair (NYSE:DINO) Q4 2025 Earnings call February 18, 2026 08:30 AM ET Company ParticipantsAtanas Atanasov - CFOCraig Biery - VP of Investor RelationsDoug Leggate - Senior Managing DirectorFranklin Myers - Interim CEOJason Gabelman - Energy Equity Research Managing DirectorManav Gupta - Executive DirectorMatt Joyce - SVP of Lubricants and SpecialtiesMatthew Blair - Managing DirectorPaul Cheng - Managing DirectorPhillip Jungwirth - Managing DirectorSteve Ledbetter - EVP of CommercialValerie Pompa - EVP ...